Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
Latest funding size
Time since last funding
|about 2 years|
|Novartis Venture Fund, Life Sciences Partners, Johnson & Johnson Innovation, Aglaia Oncology Fund, Bay City Capital, Tekla Capital Management, RA Capital Healthcare, Novo A/S, Pfizer Venture Investments, Sofinnova Ventures, Rock Springs Capital, Pfizer|